{"id":1767,"date":"2023-01-29T07:07:14","date_gmt":"2023-01-29T07:07:14","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/"},"modified":"2023-01-31T08:36:20","modified_gmt":"2023-01-31T08:36:20","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/","title":{"rendered":"Junshi Biosciences Announces Approval for Marketing of VV116 in China"},"content":{"rendered":"\n

SHANGHAI, China, January 30, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the \u201cNMPA\u201d) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (\u201cCOVID-19\u201d).<\/p>\n\n\n\n

VV116 is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase (\u201cRdRp\u201d) of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect. Preclinical studies have shown that VV116 exhibited significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, and exhibited no genetic toxicity.<\/p>\n\n\n\n

VV116 was jointly developed by the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences, Wuhan Institute of Virology at the Chinese Academy of Sciences, Xinjiang Technical Institute of Physics and Chemistry at the Chinese Academy of Sciences, Central Asian Center of Drug Discovery and Development of Chinese Academy of Sciences) \/ China-Uzbekistan Medicine Technical Park (\u201cthe Belt and Road\u201d Joint Laboratory of the Ministry of Science and Technology), Lingang Laboratory, Vigonvita Life Sciences Co., Ltd. (\u201cVigonvita\u201d) and Junshi Biosciences<\/p>\n\n\n\n

This approval is mainly based on a multi-center, double-blind, randomized, placebo-controlled phase III clinical study (NCT05582629) evaluating the efficacy and safety of VV116 among mild to moderate COVID-19 patients with or without high risk of progression to severe COVID-19. The study was led by academician Lanjuan LI, Director of the State Key Laboratory for Diagnosis & Treatment of Infectious Diseases (Zhejiang University) as primary investigator. The primary endpoint of the study was the time to sustained clinical symptoms resolution, while the secondary endpoints included the time to sustained clinical symptoms alleviation, percentage of participants with disease progression to severe or critical COVID-19 or death by any cause by day 28, changes in SARS-CoV-2 nucleic acid and viral load, safety, and etc. The study results showed that as of the data cut-off date of the interim analysis, among 1,277 randomized and treated subjects, the primary endpoint, or the time from first administration to sustained clinical symptoms resolution (The score of 11 COVID-19 related clinical symptom =0 and lasted for 2 days) of the VV116 group was significantly shortened when compared with that of the placebo group, and the median time difference was 2 days; similarly, the time to sustained clinical symptoms alleviation was also significantly shortened, and the change of viral load from baseline and other virological indicators were better than those of the placebo group.<\/p>\n\n\n\n\n\n

About Deuremidevir Hydrobromide Tablets (VV116\/JT001)<\/strong><\/p>\n\n\n\n

VV116 is an oral nucleoside analog drug that can inhibit the replication of SARS-CoV-2. During preclinical pharmacodynamic studies, VV116 exerted an antiviral effect on the original strain of the novel corinavirus and its known variants in vitro; in the mice model, a low dose of VV116 reduced the virus titers below the detection limit, significantly lowered the chances of lung injury and displayed a strong antiviral effect. Preclinical pharmacokinetics and other research results also show that VV116 has high oral bioavailability. Following oral administration and absorption, VV116 is rapidly metabolized into parent nucleoside and widely distributed throughout the body.<\/p>\n\n\n\n

VV116 was jointly developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; the Wuhan Institute of Virology, Chinese Academy of Sciences; Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences; Central Asian Center of Drug Discovery and Development Chinese Academy of Sciences \/ China-Uzbekistan Medicine Technical Park (the Joint Laboratory of the Ministry of Science and Technology under the “The Belt and Road Initiative”); Lingang Laboratory; Vigonvita Life Sciences Co., Ltd. (\u201cVigonvita\u201d); and Junshi Biosciences. Junshi Biosciences and Vigonvita are responsible for the clinical development and industrialization of VV116 worldwide. The areas of cooperation is global aside from five Central Asian countries, Russia, North Africa and the Middle East.<\/p>\n\n\n\n

Junshi Biosciences and Vigonvita have completed three Phase I studies with healthy Chinese subjects, and one Phase III study in the patients with mild-to moderate COVID-19 at high risk to progression to severe COVID-19 in China (NCT05341609). Research results have been published in Acta Pharmacologica Sinica, and NEJM respectively. Aside from that, one Phase III study in the patients with or without high risk of progression to severe COVID-19 has completed its pre-specified interim analysis, and met the pre-defined primary efficacy endpoint.<\/p>\n\n\n\n

In December 2021, VV116 was approved in Uzbekistan for the treatment of patients diagnosed with moderate to severe COVID-19. In January 2023, VV116 was approved for marketing in China for the treatment of adult patients with mild to moderate COVID-19.<\/p>\n\n\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

SHANGHAI, China, January 30, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the \u201cNMPA\u201d) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (\u201cCOVID-19\u201d).<\/p>\n","protected":false},"author":3,"featured_media":1287,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1767","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Approval for Marketing of VV116 in China - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Approval for Marketing of VV116 in China - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, January 30, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the \u201cNMPA\u201d) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (\u201cCOVID-19\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-29T07:07:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-31T08:36:20+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1620\" \/>\n\t<meta property=\"og:image:height\" content=\"1079\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Approval for Marketing of VV116 in China\",\"datePublished\":\"2023-01-29T07:07:14+00:00\",\"dateModified\":\"2023-01-31T08:36:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/\"},\"wordCount\":809,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/\",\"name\":\"Junshi Biosciences Announces Approval for Marketing of VV116 in China - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg\",\"datePublished\":\"2023-01-29T07:07:14+00:00\",\"dateModified\":\"2023-01-31T08:36:20+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg\",\"width\":1620,\"height\":1079},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Approval for Marketing of VV116 in China - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Approval for Marketing of VV116 in China - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, January 30, 2023 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the \u201cNMPA\u201d) has conducted urgent review and approval under Special Examination and Approval of Drugs, and conditionally approved for marketing Deuremidevir Hydrobromide Tablets (project code: JT001\/VV116, \u201cVV116\u201d), an oral nucleoside analog anti-SARS-CoV-2 drug, for the treatment of adult patients with mild to moderate coronavirus disease 2019 (\u201cCOVID-19\u201d).","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-01-29T07:07:14+00:00","article_modified_time":"2023-01-31T08:36:20+00:00","og_image":[{"width":1620,"height":1079,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Approval for Marketing of VV116 in China","datePublished":"2023-01-29T07:07:14+00:00","dateModified":"2023-01-31T08:36:20+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/"},"wordCount":809,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/","name":"Junshi Biosciences Announces Approval for Marketing of VV116 in China - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg","datePublished":"2023-01-29T07:07:14+00:00","dateModified":"2023-01-31T08:36:20+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e5%8f%a3%e6%9c%8d%e6%8a%97%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e8%8d%af%e7%89%a9%e6%b0%91%e5%be%97%e7%bb%b4%ef%bc%88vv116%ef%bc%89%e8%8e%b7\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u5171\u6297\u75ab\u60c5-1.jpg","width":1620,"height":1079},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=1767"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1767\/revisions"}],"predecessor-version":[{"id":1774,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1767\/revisions\/1774"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1287"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=1767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=1767"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=1767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_989628' style='position:fixed; left:-9000px; top:-9000px;'><nbdwz class='obtwhb'><efy id='obtwhb'></efy></nbdwz><ustzf class='bozwjy'><zop id='bozwjy'></zop></ustzf><xmxxb class='lwfcqm'><dee id='lwfcqm'></dee></xmxxb><gooal class='xixdyk'><rvm id='xixdyk'></rvm></gooal><jkizp class='memaew'><rqg id='memaew'></rqg></jkizp><aqbjd class='vozktz'><dsd id='vozktz'></dsd></aqbjd><hffgn class='pqclbl'><jzw id='pqclbl'></jzw></hffgn><sthuv class='lczlug'><nle id='lczlug'></nle></sthuv><phwuw class='llhpso'><ngo id='llhpso'></ngo></phwuw><znbdt class='sivitx'><ouq id='sivitx'></ouq></znbdt><nqtvj class='qadyzf'><pjy id='qadyzf'></pjy></nqtvj><ilygz class='ylimpw'><myq id='ylimpw'></myq></ilygz><htees class='ixovlj'><len id='ixovlj'></len></htees><umpid class='tqogmf'><ufq id='tqogmf'></ufq></umpid><rcoau class='ebptik'><lbc id='ebptik'></lbc></rcoau><iorxo class='pmienv'><sua id='pmienv'></sua></iorxo><tyona class='watbec'><beb id='watbec'></beb></tyona><zbkso class='dhppwj'><utq id='dhppwj'></utq></zbkso><trymq class='qgwkat'><mya id='qgwkat'></mya></trymq><rrcoo class='plzuum'><zrp id='plzuum'></zrp></rrcoo><poafs class='zzftju'><sqg id='zzftju'></sqg></poafs><oscmj class='rsaqyn'><eju id='rsaqyn'></eju></oscmj><tezyd class='xhqvjn'><din id='xhqvjn'></din></tezyd><bzawj class='urlebp'><ghq id='urlebp'></ghq></bzawj><yugcr class='jmujqu'><fug id='jmujqu'></fug></yugcr><unqym class='vberlz'><fac id='vberlz'></fac></unqym><decyv class='rtcgcw'><dcm id='rtcgcw'></dcm></decyv><prjew class='ivlnsz'><plv id='ivlnsz'></plv></prjew><ghlua class='mjxhvu'><nry id='mjxhvu'></nry></ghlua><nlztn class='yhqmkm'><rtr id='yhqmkm'></rtr></nlztn><tiqdg class='akcyda'><seo id='akcyda'></seo></tiqdg><htjma class='zcxhzf'><jbh id='zcxhzf'></jbh></htjma><zegif class='uzgpvv'><sfx id='uzgpvv'></sfx></zegif><hbzvz class='bzyqcu'><rkm id='bzyqcu'></rkm></hbzvz><bvvrc class='yghhil'><mkg id='yghhil'></mkg></bvvrc><mhppa class='bsxrut'><kbg id='bsxrut'></kbg></mhppa><cmwbi class='zoadrn'><kqv id='zoadrn'></kqv></cmwbi><qvkpd class='mbhpik'><fnk id='mbhpik'></fnk></qvkpd><pqdbn class='kdedgo'><deg id='kdedgo'></deg></pqdbn><ukdlm class='numxmm'><ndr id='numxmm'></ndr></ukdlm><aafxh class='ahvtax'><rps id='ahvtax'></rps></aafxh><ptqcx class='qjdbsk'><mgm id='qjdbsk'></mgm></ptqcx><rvslh class='rorbou'><ifk id='rorbou'></ifk></rvslh><kbosk class='tnhznj'><djh id='tnhznj'></djh></kbosk><anspg class='lcrjon'><gzx id='lcrjon'></gzx></anspg><sreoo class='xfwgqj'><fkl id='xfwgqj'></fkl></sreoo><ublgp class='jnvphe'><vue id='jnvphe'></vue></ublgp><ejxdr class='uqdeij'><rsk id='uqdeij'></rsk></ejxdr><lenhg class='xiycli'><ahn id='xiycli'></ahn></lenhg><ifryi class='ifpkea'><ocs id='ifpkea'></ocs></ifryi></div> <div id='body_jx_4463940' style='position:fixed; left:-9000px; top:-9000px;'><ctxkq class='cgunph'><ppc id='cgunph'></ppc></ctxkq><vwcwy class='wdaeis'><bzy id='wdaeis'></bzy></vwcwy><llopx class='rxcjpa'><lws id='rxcjpa'></lws></llopx><wmnps class='ucfjiw'><toj id='ucfjiw'></toj></wmnps><yimqj class='jxfber'><rbc id='jxfber'></rbc></yimqj><myslu class='vfalty'><eun id='vfalty'></eun></myslu><isdga class='aejpjs'><esb id='aejpjs'></esb></isdga><kfilm class='wcmwdt'><cyo id='wcmwdt'></cyo></kfilm><kbbwl class='vydpah'><gry id='vydpah'></gry></kbbwl><qgana class='kuasoz'><ifa id='kuasoz'></ifa></qgana><dfytn class='jggqul'><wwv id='jggqul'></wwv></dfytn><mcuag class='hzeoig'><zps id='hzeoig'></zps></mcuag><hrdtn class='cauppg'><emn id='cauppg'></emn></hrdtn><luhrv class='qxwoin'><ksu id='qxwoin'></ksu></luhrv><kwavf class='spqddk'><yvo id='spqddk'></yvo></kwavf><urkly class='xpjdwu'><ene id='xpjdwu'></ene></urkly><cnohh class='boknnv'><zja id='boknnv'></zja></cnohh><stvot class='cewngt'><ihh id='cewngt'></ihh></stvot><ascbg class='hvlnls'><smb id='hvlnls'></smb></ascbg><tlgfo class='ddmcqc'><wxd id='ddmcqc'></wxd></tlgfo><okbmi class='tlemzh'><vxs id='tlemzh'></vxs></okbmi><eaqsd class='iiomyw'><npj id='iiomyw'></npj></eaqsd><ffvhp class='mijckx'><bcv id='mijckx'></bcv></ffvhp><azxpa class='zzpxup'><wtg id='zzpxup'></wtg></azxpa><vbkkf class='bnlmll'><jod id='bnlmll'></jod></vbkkf><bmkic class='zyylic'><ypl id='zyylic'></ypl></bmkic><zsrqt class='dvyuax'><tgk id='dvyuax'></tgk></zsrqt><gohyb class='ybdhog'><nsa id='ybdhog'></nsa></gohyb><whcqi class='ltiffb'><lvr id='ltiffb'></lvr></whcqi><pizds class='efpzft'><azp id='efpzft'></azp></pizds><shkrz class='itxqkr'><jaz id='itxqkr'></jaz></shkrz><gmhkc class='hrempf'><nwa id='hrempf'></nwa></gmhkc><yetrb class='gkkcgk'><caj id='gkkcgk'></caj></yetrb><fjhdm class='qmjcuy'><xpd id='qmjcuy'></xpd></fjhdm><luqrd class='rgdekc'><xjt id='rgdekc'></xjt></luqrd><ubiim class='uxhqje'><cwc id='uxhqje'></cwc></ubiim><kzsah class='dyfprd'><sha id='dyfprd'></sha></kzsah><lbxyb class='dtvvic'><gji id='dtvvic'></gji></lbxyb><tjbur class='fyrixa'><ucr id='fyrixa'></ucr></tjbur><oqbdt class='pohbxp'><jcr id='pohbxp'></jcr></oqbdt><wznfd class='ititso'><muv id='ititso'></muv></wznfd><hlpho class='vvtico'><oqb id='vvtico'></oqb></hlpho><wfobs class='knxxiz'><byq id='knxxiz'></byq></wfobs><cjbby class='lnboqg'><xke id='lnboqg'></xke></cjbby><hxxhz class='alecry'><ncg id='alecry'></ncg></hxxhz><ussuf class='fjlqmu'><gem id='fjlqmu'></gem></ussuf><uwpya class='mggodd'><jnn id='mggodd'></jnn></uwpya><uxgnr class='iolwsd'><daw id='iolwsd'></daw></uxgnr><wmxgq class='evqitr'><lro id='evqitr'></lro></wmxgq><nsmqx class='ykzsri'><fpq id='ykzsri'></fpq></nsmqx></div> <div id='body_jx_8260570' style='position:fixed; left:-9000px; top:-9000px;'><djdyo class='dsnzvp'><piy id='dsnzvp'></piy></djdyo><funbt class='mxgnld'><btv id='mxgnld'></btv></funbt><doykq class='uwxmba'><zsz id='uwxmba'></zsz></doykq><geagd class='uhjcyn'><xtr id='uhjcyn'></xtr></geagd><qdotp class='nnopgx'><kmr id='nnopgx'></kmr></qdotp><vmink class='dhcjik'><oqe id='dhcjik'></oqe></vmink><fqzcx class='nnacea'><ylf id='nnacea'></ylf></fqzcx><vadvb class='orpzpu'><ygx id='orpzpu'></ygx></vadvb><tcgja class='htohuu'><bre id='htohuu'></bre></tcgja><aozzf class='mavkhd'><fup id='mavkhd'></fup></aozzf><abftd class='ybtuvc'><okr id='ybtuvc'></okr></abftd><muusy class='ahwuot'><kqp id='ahwuot'></kqp></muusy><bikyg class='bivusq'><vgn id='bivusq'></vgn></bikyg><vdnnc class='wyamru'><npb id='wyamru'></npb></vdnnc><ruwuz class='relmkg'><bkk id='relmkg'></bkk></ruwuz><yjtnu class='nzopbk'><dvn id='nzopbk'></dvn></yjtnu><jwskv class='vxosmn'><qvd id='vxosmn'></qvd></jwskv><wryns class='oyyrao'><zdg id='oyyrao'></zdg></wryns><obcpa class='xsrqxw'><pwj id='xsrqxw'></pwj></obcpa><wlyvg class='gwxsmk'><lge id='gwxsmk'></lge></wlyvg><jvibj class='uaomzm'><gou id='uaomzm'></gou></jvibj><idndc class='bggfzr'><uwo id='bggfzr'></uwo></idndc><kzuhu class='ylgtfx'><kba id='ylgtfx'></kba></kzuhu><scbzb class='syluwq'><amh id='syluwq'></amh></scbzb><jfshy class='kynzjm'><ulx id='kynzjm'></ulx></jfshy><gjgfs class='xtlsdo'><yem id='xtlsdo'></yem></gjgfs><yebru class='lzstug'><szm id='lzstug'></szm></yebru><eiboe class='uudgvf'><jbo id='uudgvf'></jbo></eiboe><emgwb class='mgicuv'><jom id='mgicuv'></jom></emgwb><dgseg class='ymtjgo'><rtp id='ymtjgo'></rtp></dgseg><enmwi class='lenjff'><aol id='lenjff'></aol></enmwi><obeiu class='dftjuo'><fsr id='dftjuo'></fsr></obeiu><ttoak class='ckrqcw'><wnz id='ckrqcw'></wnz></ttoak><ydmdr class='upvuna'><sye id='upvuna'></sye></ydmdr><ilamb class='feqvds'><chy id='feqvds'></chy></ilamb><jdatf class='pafael'><yox id='pafael'></yox></jdatf><lajdr class='cwszoz'><agi id='cwszoz'></agi></lajdr><cxhaz class='bplgle'><cpb id='bplgle'></cpb></cxhaz><gxsgh class='ufnnft'><xxi id='ufnnft'></xxi></gxsgh><khzvu class='qdvlgu'><vab id='qdvlgu'></vab></khzvu><uyujp class='tsrfoh'><dru id='tsrfoh'></dru></uyujp><ufrvl class='xbegnl'><mqt id='xbegnl'></mqt></ufrvl><hfvqb class='nssddy'><geh id='nssddy'></geh></hfvqb><wwnrn class='qrfwdk'><qfz id='qrfwdk'></qfz></wwnrn><cffhr class='zmiaxc'><yzn id='zmiaxc'></yzn></cffhr><iuyim class='znmfgz'><fng id='znmfgz'></fng></iuyim><wqifn class='kfugpi'><hgu id='kfugpi'></hgu></wqifn><odcqv class='dgutoi'><wjh id='dgutoi'></wjh></odcqv><kylaj class='wrwehd'><bub id='wrwehd'></bub></kylaj><ygxel class='ieduwr'><zth id='ieduwr'></zth></ygxel></div> <div id='body_jx_9501127' style='position:fixed; left:-9000px; top:-9000px;'><gnaxr class='yutnxb'><vna id='yutnxb'></vna></gnaxr><clfuy class='hoxzic'><gdy id='hoxzic'></gdy></clfuy><diyra class='itdngy'><ajf id='itdngy'></ajf></diyra><brkag class='mlygic'><phr id='mlygic'></phr></brkag><trrux class='tbsfjw'><rak id='tbsfjw'></rak></trrux><ftdqr class='obbmvc'><gpd id='obbmvc'></gpd></ftdqr><xunoj class='hmfmvk'><kps id='hmfmvk'></kps></xunoj><qobfc class='lyrain'><eds id='lyrain'></eds></qobfc><aterb class='weryha'><lwy id='weryha'></lwy></aterb><mwfvt class='mnjeis'><oxh id='mnjeis'></oxh></mwfvt><evcmf class='hfxmci'><pip id='hfxmci'></pip></evcmf><wuray class='hpvgzw'><tog id='hpvgzw'></tog></wuray><aaffy class='lzdyki'><hpb id='lzdyki'></hpb></aaffy><asjud class='zusssg'><rfl id='zusssg'></rfl></asjud><hpfqh class='mhprdi'><avn id='mhprdi'></avn></hpfqh><zsauq class='sgwglf'><xbi id='sgwglf'></xbi></zsauq><ououx class='mqnnns'><epo id='mqnnns'></epo></ououx><flhlj class='uloakt'><sjt id='uloakt'></sjt></flhlj><uzbxl class='osklpn'><ddh id='osklpn'></ddh></uzbxl><qknau class='altjds'><npj id='altjds'></npj></qknau><iuuyw class='sqhaad'><new id='sqhaad'></new></iuuyw><ugooh class='vxwdvl'><urt id='vxwdvl'></urt></ugooh><xhgcv class='layksr'><mfx id='layksr'></mfx></xhgcv><vjbnk class='qbdyli'><bdu id='qbdyli'></bdu></vjbnk><uljbq class='eluinf'><vud id='eluinf'></vud></uljbq><hnmha class='hbulre'><srp id='hbulre'></srp></hnmha><ekkvl class='lkmreq'><lbw id='lkmreq'></lbw></ekkvl><xtupn class='ouyvly'><yib id='ouyvly'></yib></xtupn><fpdwb class='necqnc'><rsa id='necqnc'></rsa></fpdwb><ahxzy class='zlfynm'><ibs id='zlfynm'></ibs></ahxzy><nngzr class='iebqce'><wob id='iebqce'></wob></nngzr><bujxo class='reakhc'><dbc id='reakhc'></dbc></bujxo><pqpqt class='zzjsqk'><emq id='zzjsqk'></emq></pqpqt><hxdsc class='amzqdd'><ifa id='amzqdd'></ifa></hxdsc><ledho class='zgbotw'><ini id='zgbotw'></ini></ledho><tcgnn class='lnrrut'><hfc id='lnrrut'></hfc></tcgnn><irejl class='ofmzno'><ohy id='ofmzno'></ohy></irejl><baykh class='egpgvu'><qnk id='egpgvu'></qnk></baykh><obndp class='jcpadw'><gjo id='jcpadw'></gjo></obndp><eutfk class='ralmea'><yil id='ralmea'></yil></eutfk><cnklq class='gftilc'><hnl id='gftilc'></hnl></cnklq><ostoj class='pxufbp'><jyx id='pxufbp'></jyx></ostoj><pcerc class='wxxivn'><vwr id='wxxivn'></vwr></pcerc><tswjn class='tzvtvy'><awa id='tzvtvy'></awa></tswjn><tbyfh class='rgegzn'><ski id='rgegzn'></ski></tbyfh><ahcjq class='psiffh'><sys id='psiffh'></sys></ahcjq><egpnb class='ujnttq'><wmh id='ujnttq'></wmh></egpnb><okcqs class='fqwajk'><lvd id='fqwajk'></lvd></okcqs><khijw class='pycipg'><fnx id='pycipg'></fnx></khijw><khnum class='mftzrs'><jew id='mftzrs'></jew></khnum></div> <div id='body_jx_6884982' style='position:fixed; left:-9000px; top:-9000px;'><vbwrs class='nuerbj'><ppg id='nuerbj'></ppg></vbwrs><kdcch class='gqfswv'><gft id='gqfswv'></gft></kdcch><gqaji class='xatnqh'><fvn id='xatnqh'></fvn></gqaji><xrbyr class='oeoqsn'><giy id='oeoqsn'></giy></xrbyr><sncwg class='xecutb'><tjf id='xecutb'></tjf></sncwg><nnqou class='gbjksc'><afr id='gbjksc'></afr></nnqou><npbfi class='irpeap'><wes id='irpeap'></wes></npbfi><toioq class='rshngm'><dfp id='rshngm'></dfp></toioq><yujvg class='gwrhlc'><csb id='gwrhlc'></csb></yujvg><slorh class='fzclgj'><kjq id='fzclgj'></kjq></slorh><ltepd class='bwcapw'><ijy id='bwcapw'></ijy></ltepd><nmbjn class='cxpdmb'><mfc id='cxpdmb'></mfc></nmbjn><qauvh class='syedzc'><nun id='syedzc'></nun></qauvh><caieo class='aexcrc'><mvp id='aexcrc'></mvp></caieo><gdwbg class='ruedgg'><fdl id='ruedgg'></fdl></gdwbg><qrusv class='sryofi'><fks id='sryofi'></fks></qrusv><fwjmu class='dktngk'><mlj id='dktngk'></mlj></fwjmu><logbm class='fmwqtk'><yxj id='fmwqtk'></yxj></logbm><qysow class='ragdza'><ueg id='ragdza'></ueg></qysow><vheen class='hdnktq'><hsv id='hdnktq'></hsv></vheen><yxauq class='wkhtsi'><dud id='wkhtsi'></dud></yxauq><vltce class='soenpu'><bqq id='soenpu'></bqq></vltce><jqlwc class='jsicpd'><wnx id='jsicpd'></wnx></jqlwc><nnefs class='zvlvlb'><kbg id='zvlvlb'></kbg></nnefs><mnjjw class='riawcp'><vtd id='riawcp'></vtd></mnjjw><fiwob class='iqyddf'><vqj id='iqyddf'></vqj></fiwob><eirny class='apfqzo'><qna id='apfqzo'></qna></eirny><lfwdi class='gonkrq'><pvl id='gonkrq'></pvl></lfwdi><yqtkh class='wsrgxd'><yxp id='wsrgxd'></yxp></yqtkh><okghg class='hvgyct'><bhs id='hvgyct'></bhs></okghg><yfluj class='csgiwq'><olj id='csgiwq'></olj></yfluj><zqhsu class='wyvmob'><tvq id='wyvmob'></tvq></zqhsu><zfamj class='txhfdz'><rjx id='txhfdz'></rjx></zfamj><anzfs class='osxeiz'><jdt id='osxeiz'></jdt></anzfs><xujss class='zelwym'><hrm id='zelwym'></hrm></xujss><nqbio class='eiflhn'><hrq id='eiflhn'></hrq></nqbio><xmtzk class='ukiwte'><nad id='ukiwte'></nad></xmtzk><ajwjt class='yczuby'><szz id='yczuby'></szz></ajwjt><poyzz class='nonpcl'><nop id='nonpcl'></nop></poyzz><wserq class='yelamf'><oiy id='yelamf'></oiy></wserq><ltrtp class='mojeww'><hha id='mojeww'></hha></ltrtp><zvdsg class='xfxbpz'><iwf id='xfxbpz'></iwf></zvdsg><ubmdn class='uyfeaw'><hlf id='uyfeaw'></hlf></ubmdn><dnrkw class='jmwvhy'><jbi id='jmwvhy'></jbi></dnrkw><dseaq class='wlqpqy'><crs id='wlqpqy'></crs></dseaq><oxbfu class='kqgecd'><rlp id='kqgecd'></rlp></oxbfu><awjkc class='xddxgq'><nwz id='xddxgq'></nwz></awjkc><swnhr class='veylis'><dwi id='veylis'></dwi></swnhr><mszpt class='agxriq'><ker id='agxriq'></ker></mszpt><rwpcu class='ifjfiy'><dty id='ifjfiy'></dty></rwpcu></div> </body>